{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Edwards Lifesciences Reports First Quarter Results - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"t1Zk5es31r\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-lifesciences-reports-first-quarter-results\/\">Edwards Lifesciences Reports First Quarter Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/edwards-lifesciences-reports-first-quarter-results\/embed\/#?secret=t1Zk5es31r\" width=\"600\" height=\"338\" title=\"&#8220;Edwards Lifesciences Reports First Quarter Results&#8221; &#8212; Market Newsdesk\" data-secret=\"t1Zk5es31r\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire IRVINE, Calif., April\u00a020, 2021 \/PRNewswire\/ &#8212;\u00a0Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March\u00a031, 2021.\u00a0 First Quarter Highlights and 2021 Outlook Sales grew 8 percent to $1.2 billion; underlying1 sales grew 5 percent TAVR sales grew 7 percent; underlying sales grew 4 percent EPS of $0.54 exceeded expectations Received approval for a U.S. pivotal trial for TAVR in moderate AS patients Received TAVR approval in Japan for patients at low surgical risk First patients were treated with EVOQUE Eos transcatheter mitral replacement system Initiated TRISCEND II U.S. pivotal trial for transcatheter tricuspid replacement Completed Accelerated Share Repurchase Continued confidence in sales outlook; Adjusted EPS guidance of $2.07 to $2.27 increased $0.07 &#8220;We recognize that &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/127172\/edwards_lifesciences_corporation_logo.jpg"}